Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy in Severe Aplastic Anemia
NCT06695741Phase 2Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Nov 2024; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06695741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695741.